NASDAQ · Health care

BioAtla, Inc. (BCAB)

It posted a net loss of $31.5M. At June 30, 2026 it held $1.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$1.48

-2.63% on the day · September 25, 2026

52-week range $1.07 to $71.50

Market cap

$2.5M

What BioAtla, Inc. does

BioAtla, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BCAB.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$59.3M	-$59.6M	-$1.01	n/a
2024	n/a	-$73.9M	-$69.8M	-$1.44	n/a
2023	n/a	-$129.7M	-$123.5M	-$2.58	n/a
2022	n/a	-$108.1M	-$106.5M	-$2.74	n/a
2021	$300K	-$96.4M	-$95.4M	-$2.76	n/a
2021	n/a	-$30.1M	-$35.9M	-$3.19	n/a

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What BioAtla, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 28, 2026
Stock exchange listing notice 8-K
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.27 versus -$15.99.
July 16, 2026
Shareholder vote results 8-K
June 3, 2026
Annual report to shareholders ARS
June 3, 2026
Additional proxy material DEFA14A
June 3, 2026
Proxy statement DEF 14A
May 15, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$4.22 versus -$13.16.
April 29, 2026
Annual report (amended) 10-K/A · period to December 31, 2025Diluted EPS -$1.01 versus -$1.44.
April 2, 2026
Other event 8-K
March 31, 2026
Employee stock plan registration S-8

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 2, 2026. Insider transactions on SEC

Insider trades

What the people running BioAtla, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
August 31, 2026	Vasquez ChristianChief Financial Officer	Shares withheld for tax	71	$1.69	$120	Form 4
August 31, 2026	Short Jay M PhdChief Executive Officer, Director	Shares withheld for tax	259	$1.69	$437.7	Form 4
August 31, 2026	Sievers EricChief Medical Officer	Shares withheld for tax	134	$1.69	$226.5	Form 4
May 31, 2026	Sievers EricChief Medical Officer	Shares withheld for tax	134	$3.93	$526.6	Form 4
May 31, 2026	Vasquez ChristianChief Financial Officer	Shares withheld for tax	82	$3.93	$322.3	Form 4
May 31, 2026	Short Jay M PhdChief Executive Officer, Director	Shares withheld for tax	259	$3.93	$1K	Form 4
March 12, 2026	Short Jay M PhdChief Executive Officer, Director	Shares withheld for tax	639	$0.17	$107.4	Form 4
March 11, 2026	Sievers EricChief Medical Officer	Shares withheld for tax	360	$0.17	$60.8	Form 4
March 11, 2026	Vasquez ChristianChief Financial Officer	Shares withheld for tax	175	$0.17	$29.6	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BCAB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 73,857 shares in total, about $109.3K at the last price.

Holder	Shares	As of
Short Jay M PhdChief Executive Officer, Director	52,035	August 31, 2026
Sievers EricChief Medical Officer	11,346	August 31, 2026
Vasquez ChristianChief Financial Officer	10,476	August 31, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BCAB

What does BioAtla, Inc. do?

BioAtla, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BCAB.

Is BioAtla, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $31.5M.

When did BioAtla, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Compare BCAB with

Compare BCAB with any company

Follow BCAB

Get an email when BioAtla, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BCAB: get an email when it files

Where the numbers come from

Financial figures are the values BioAtla, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.